[HTML][HTML] Understanding thrombosis with thrombocytopenia syndrome after COVID-19 vaccination

A Buoninfante, A Andeweg, AT Baker, M Borad… - npj Vaccines, 2022 - nature.com
Safety and efficacy of vaccines against the SARS-CoV-2 coronavirus has been
demonstrated in clinical trials and next by their real world use through the course of the …

Transforming and evaluating the UK Biobank to the OMOP Common Data Model for COVID-19 research and beyond

V Papez, M Moinat, EA Voss, S Bazakou… - Journal of the …, 2023 - academic.oup.com
Objective The coronavirus disease 2019 (COVID-19) pandemic has demonstrated the value
of real-world data for public health research. International federated analyses are crucial for …

Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort …

X Li, E Burn, T Duarte-Salles, C Yin, C Reich… - bmj, 2022 - bmj.com
Objective To quantify the comparative risk of thrombosis with thrombocytopenia syndrome or
thromboembolic events associated with use of adenovirus based covid-19 vaccines versus …

[HTML][HTML] Contextualising adverse events of special interest to characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases: a …

EA Voss, A Shoaibi, LYH Lai, C Blacketer… - …, 2023 - thelancet.com
Background Adverse events of special interest (AESIs) were pre-specified to be monitored
for the COVID-19 vaccines. Some AESIs are not only associated with the vaccines, but with …

[图书][B] Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19)

World Health Organization - 2023 - books.google.com
Thrombotic Thrombocytopenia Syndrome (TTS) has emerged as a new adverse event
following immunization in individuals vaccinated with COVID-19 non-replicant adenovirus …

[HTML][HTML] Thrombosis with thrombocytopenia syndrome: A database review of clinical trial and post-marketing experience with Ad26. COV2. S

F Struyf, K Hardt, R Van Rampelbergh, G Shukarev… - Vaccine, 2023 - Elsevier
Background Thrombosis with thrombocytopenia syndrome (TTS) is a very rare disorder
described after vaccination with adenoviral vector-based COVID-19 vaccines. Co-occurring …

[HTML][HTML] Characterising the treatment of thromboembolic events after COVID-19 vaccination in 4 European countries and the US: An international network cohort study

AF Markus, VY Strauss, E Burn, X Li… - Frontiers in …, 2023 - frontiersin.org
Background: Thrombosis with thrombocytopenia syndrome (TTS) has been identified as a
rare adverse event following some COVID-19 vaccines. Various guidelines have been …

Incidence rates of thrombosis with thrombocytopenia syndrome (TTS) among adults in United States commercial and Medicare claims databases, 2017–2020

PC Lloyd, B Lufkin, K Moll, RP Ogilvie… - Vaccine, 2024 - Elsevier
Background Increased risk of thrombosis with thrombocytopenia syndrome (TTS) following
adenovirus vector-based COVID-19 vaccinations has been identified in passive surveillance …

CohortDiagnostics: phenotype evaluation across a network of observational data sources using population-level characterization

GA Rao, A Shoaibi, R Makadia, J Hardin, J Swerdel… - medRxiv, 2023 - medrxiv.org
Objective: This paper introduces a novel framework for evaluating phenotype algorithms
(PAs) using the open-source tool, Cohort Diagnostics. Materials and Methods: The method …

[图书][B] Generating Reliable and Responsive Observational Evidence: Reducing Pre-analysis Bias

A Ostropolets - 2023 - search.proquest.com
A growing body of evidence generated from observational data has demonstrated the
potential to influence decision-making and improve patient outcomes. For observational …